497 related articles for article (PubMed ID: 19004406)
1. Indoleamine 2,3-dioxygenase expression in gestational trophoblastic disease: implications for development of immunotherapeutic approaches.
Sebire NJ; Fisher RA; Williams S; Prendergast G; Savage P; Seckl M
J Reprod Med; 2008 Oct; 53(10):789-92. PubMed ID: 19004406
[TBL] [Abstract][Full Text] [Related]
2. Expression of maspin in gestational trophoblastic disease.
Li HW; Leung SW; Cheung AN; Yu MM; Chan LK; Wong YF
Gynecol Oncol; 2006 Apr; 101(1):76-81. PubMed ID: 16271752
[TBL] [Abstract][Full Text] [Related]
3. Current issues in the histopathology of gestational trophoblastic tumors.
Sebire NJ; Lindsay I
Fetal Pediatr Pathol; 2010; 29(1):30-44. PubMed ID: 20055562
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia.
Menczer J; Schreiber L; Berger E; Golan A; Levy T
Gynecol Oncol; 2007 Mar; 104(3):675-9. PubMed ID: 17126893
[TBL] [Abstract][Full Text] [Related]
5. p57(KIP2) immunohistochemical staining of gestational trophoblastic tumours does not identify the type of the causative pregnancy.
Sebire NJ; Rees HC; Peston D; Seckl MJ; Newlands ES; Fisher RA
Histopathology; 2004 Aug; 45(2):135-41. PubMed ID: 15279631
[TBL] [Abstract][Full Text] [Related]
6. Cell proliferative activity and mutation of P53 suppressor gene in human gestational trophoblastic disease.
Persaud V; Ganjei P; Nadji M
West Indian Med J; 1993 Dec; 42(4):142-3. PubMed ID: 7909185
[TBL] [Abstract][Full Text] [Related]
7. Incidence of postmolar gestational trophoblastic disease in androgenetic moles and the morphological features associated with low risk postmolar gestational trophoblastic disease.
Kaneki E; Kobayashi H; Hirakawa T; Matsuda T; Kato H; Wake N
Cancer Sci; 2010 Jul; 101(7):1717-21. PubMed ID: 20518791
[TBL] [Abstract][Full Text] [Related]
8. Detection of HASH2 (ASCL2) gene expression in gestational trophoblastic disease.
Shahib MN; Martaadisoebrata D; Kato H
J Reprod Med; 2006 Nov; 51(11):892-6. PubMed ID: 17165436
[TBL] [Abstract][Full Text] [Related]
9. P63 expression in hydropic abortion and gestational trophoblastic diseases.
Ramalho LN; Maggiori MS; Ribeiro-Silva A; Peres LC
Placenta; 2006; 27(6-7):740-3. PubMed ID: 16026831
[TBL] [Abstract][Full Text] [Related]
10. Mcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: a differential expression study.
Fong PY; Xue WC; Ngan HY; Chan KY; Khoo US; Tsao SW; Chiu PM; Man LS; Cheung AN
Cancer; 2005 Jan; 103(2):268-76. PubMed ID: 15578716
[TBL] [Abstract][Full Text] [Related]
11. Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease.
Lewis GH; DeScipio C; Murphy KM; Haley L; Beierl K; Mosier S; Tandy S; Cohen DS; Lytwyn A; Elit L; Vang R; Ronnett BM
Int J Gynecol Pathol; 2013 Mar; 32(2):199-214. PubMed ID: 23370656
[TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor.
Tuncer ZS; Vegh GL; Fulop V; Genest DR; Mok SC; Berkowitz RS
Gynecol Oncol; 2000 Jun; 77(3):389-93. PubMed ID: 10831347
[TBL] [Abstract][Full Text] [Related]
13. Histologic classification and staging of gestational trophoblastic disease.
Horn LC; Bilek K
Gen Diagn Pathol; 1997 Nov; 143(2-3):87-101. PubMed ID: 9443566
[TBL] [Abstract][Full Text] [Related]
14. The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy.
Niemann I; Hansen ES; Sunde L
Gynecol Oncol; 2007 Feb; 104(2):411-5. PubMed ID: 17011616
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53.
Soper JT; Mutch DG; Schink JC;
Gynecol Oncol; 2004 Jun; 93(3):575-85. PubMed ID: 15196847
[TBL] [Abstract][Full Text] [Related]
16. Relaxation of imprinting in trophoblastic disease.
Ariel I; Lustig O; Oyer CE; Elkin M; Gonik B; Rachmilewitz J; Biran H; Goshen R; de Groot N; Hochberg A
Gynecol Oncol; 1994 May; 53(2):212-9. PubMed ID: 8188082
[TBL] [Abstract][Full Text] [Related]
17. The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles.
Baasanjav B; Usui H; Kihara M; Kaku H; Nakada E; Tate S; Mitsuhashi A; Matsui H; Shozu M
Hum Reprod; 2010 May; 25(5):1183-91. PubMed ID: 20208060
[TBL] [Abstract][Full Text] [Related]
18. Molecular biology of gestational trophoblastic neoplasia: a review.
Fulop V; Mok SC; Berkowitz RS
J Reprod Med; 2004 Jun; 49(6):415-22. PubMed ID: 15283047
[TBL] [Abstract][Full Text] [Related]
19. Analysis of p53, BCL-2 and epidermal growth factor receptor protein expression in the partial and complete hydatidiform moles.
Hussein MR
Exp Mol Pathol; 2009 Aug; 87(1):63-9. PubMed ID: 19348791
[TBL] [Abstract][Full Text] [Related]
20. Genetic aspects of gestational trophoblastic diseases: a general overview with emphasis on new approaches in determining genetic composition.
Lage JM; Sheikh SS
Gen Diagn Pathol; 1997 Nov; 143(2-3):109-15. PubMed ID: 9443568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
